8-K: Instil Bio In-Licenses Promising Cancer Therapies and Reports Q3 2024 Financials

Instil Bio has licensed a potential best-in-class bispecific antibody and provided a corporate update alongside its third quarter 2024 financial results.

Summary

• Instil Bio announced the in-licensing of SYN-2510, a PD-L1xVEGF bispecific antibody, and SYN-27M, a CTLA-4 antibody, for global development outside of China.
• ImmuneOnco, Instil's partner, has dosed approximately 65 additional patients with SYN-2510 monotherapy in China, building on the initial 33 patients reported at ASCO 2024.
• Clinical data update for SYN-2510 monotherapy in China is expected in the first half of 2025.
• Phase 1b/2 studies of SYN-2510 in combination with chemotherapy are anticipated to begin in China in late 2024 for non-small cell lung cancer and in the first half of 2025 for triple-negative breast cancer.
• Instil is targeting the initiation of a U.S. clinical study of SYN-2510 in non-small cell lung cancer in the second half of 2025.
• Instil reported $122.9 million in cash, cash equivalents, marketable securities, and long-term investments as of September 30, 2024, compared to $175.0 million at the end of 2023.
• The company expects its current cash position to fund operations beyond 2026.
• In-process research and development expenses were $10.0 million for both the three and nine months ended September 30, 2024.
• Research and development expenses were $0.6 million and $10.7 million for the three and nine months ended September 30, 2024, respectively.
• Net loss per share was $3.54 and $9.57 for the three and nine months ended September 30, 2024, respectively.

Sentiment

Score: 6

Explanation: The document presents a mix of positive developments, such as the in-licensing of new therapies and progress in clinical trials, alongside negative financial results, including a significant net loss and a decrease in cash reserves. The sentiment is cautiously optimistic, with potential for future growth but also significant financial challenges.

Positives

• The in-licensing of SYN-2510 and SYN-27M expands Instil's pipeline with promising cancer therapies.
• The progress of SYN-2510 clinical trials in China, with additional patients dosed, is encouraging.
• The initiation of Phase 1b/2 studies in China for SYN-2510 in combination with chemotherapy is a positive step.
• Instil's cash position is expected to fund operations beyond 2026, providing financial stability.
• The company is actively working to expand its clinical development program into the US.

Negatives

• Instil's cash reserves decreased from $175.0 million at the end of 2023 to $122.9 million as of September 30, 2024.
• The company reported a net loss per share of $3.54 for the three months ended September 30, 2024, and $9.57 for the nine months ended September 30, 2024.
• Research and development expenses decreased significantly compared to the same periods in 2023, which may indicate a slowdown in internal research activities.

Risks

• The clinical development of SYN-2510 and SYN-27M is subject to the risks and uncertainties of the drug development process.
• The company relies on collaborators, including ImmuneOnco, for clinical trials and data generation, which introduces risks related to third-party performance.
• Regulatory approvals for the therapies are not guaranteed and are subject to the time-consuming and uncertain regulatory approval process.
• Macroeconomic conditions, including international conflicts and U.S.-China trade tensions, could adversely affect the company's business and operations.
• The company's cash resources may not be sufficient to complete all planned development programs.

Future Outlook

Instil expects its current cash position to fund operations beyond 2026 and is targeting the initiation of a U.S. clinical study of SYN-2510 in NSCLC in the second half of 2025.

Management Comments

• Our recent license of SYN-2510 is a significant milestone for Instil, positioning us with a potentially best-in-class asset in one of the most significant areas of interest in oncology, said Bronson Crouch, CEO of Instil.
• As we continue to build our internal team to operationalize the clinical development of SYN-2510, we are excited for the progress ImmuneOnco continues to make in advancing the program in its China trials.

Industry Context

The in-licensing of a bispecific antibody and a CTLA-4 antibody aligns with the industry's focus on developing novel immunotherapies for cancer. The collaboration with ImmuneOnco highlights the increasing importance of global partnerships in drug development.

Comparison to Industry Standards

• Instil's in-licensing of SYN-2510, a PD-L1xVEGF bispecific antibody, is comparable to other companies developing bispecific antibodies, such as Xencor with their pipeline of XmAb bispecific antibodies.
• The clinical development of SYN-27M, a CTLA-4 antibody, is similar to other companies exploring CTLA-4 inhibitors, such as Bristol Myers Squibb with Yervoy (ipilimumab).
• The company's cash runway extending beyond 2026 is a positive sign, but it is important to compare this to other clinical-stage biopharmaceutical companies, such as Iovance Biotherapeutics, which also has a focus on cell therapies.
• The reported net loss per share is typical for a clinical-stage company, but it is important to monitor the trend and compare it to peers like Adaptimmune Therapeutics, which is also developing novel cancer therapies.

Stakeholder Impact

• Shareholders may be encouraged by the in-licensing of new therapies and the progress in clinical trials, but concerned about the financial losses and cash burn.
• Employees may be motivated by the company's expansion and clinical development efforts, but also aware of the financial challenges.
• Customers and patients may benefit from the development of new cancer therapies.
• Suppliers and creditors may be impacted by the company's financial performance and cash position.

Next Steps

• ImmuneOnco will provide a clinical data update for SYN-2510 monotherapy in China in the first half of 2025.
• ImmuneOnco will initiate Phase 1b/2 studies of SYN-2510 in combination with chemotherapy in China in late 2024 for NSCLC and in the first half of 2025 for TNBC.
• Instil is targeting the initiation of a U.S. clinical study of SYN-2510 in NSCLC in the second half of 2025.

Key Dates

Keywords

Instil Bio, SYN-2510, IMM2510, SYN-27M, IMM27M, bispecific antibody, PD-L1xVEGF, CTLA-4 antibody, cancer therapy, clinical trials, non-small cell lung cancer, triple negative breast cancer, financial results, biopharmaceutical